← Eichor
Study identifier: NCT05834244 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

Condition: Acute Myeloid Leukemia  ·  Sponsor: M.D. Anderson Cancer Center

PhasePhase 1
Planned participants32
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To learn if adding a healthy person's natural killer (NK) cells to the combination of Azacitidine and Venetoclax can help to control AML. NK cells are cancer- and infection-fighting immune cells.

This description comes directly from the study's public registry record.

Talk to the study team

Abhishek Maiti, MD  ·  713-792-7305  ·  amaiti@mdanderson.org

Always discuss trial participation with your own doctor first.

Locations (2)

Case Western Reserve UniversityCleveland, Ohio, United StatesRecruiting
M.D. Anderson Cancer CenterHouston, Texas, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05834244